期刊文献+

石墨炉原子吸收分光光度法测定大鼠血浆和尿液中的赛特铂 被引量:2

The determination of satraplatin in rat plasma and urine by graphite furnace atomic absorption spectrometry
下载PDF
导出
摘要 目的建立大鼠血浆和尿液中赛特铂含量测定的无火焰石墨炉原子吸收分光光度法。方法采用岛津AA-670原子吸收分光光度仪及GFA-4A石墨炉,上海电光KY-1铂空心阴极灯,检测波长265.9 nm,测定大鼠血浆和尿液中的赛特铂含量。血尿样品用Triton X-100稀释,进样50μL。结果在浓度范围0.25 mg.L-1~10.0 mg.L-1内,样品峰面积与浓度呈良好线性关系,相关系数r2分别为血浆0.9952,尿液0.9878;加样回收率为血浆89%~112%,尿液82%~100%。结论方法简便可靠,适于生物样本中的赛特铂含量测定和动物药动学研究。 OBJECTIVE To develop a rapid,accurate and sensitive method for the measurements of satraplatin in biological fluids of rats.METHODS Satraplatin in plasma and urine was analyzed by flameless atomic absorption spectrometry on an instrument Shimadzu AA-670 atomic absorption spectrophotometer equipped with a Shimadzu GFA-4A graphite furnace,and an ASC-60 autosampler.The detection wavelength was set at 265.9 nm.Plasma and urine samples were diluted with Triton X-100 before assays,fifty microliters of solution after preparation was injected to the system. RESULTS The linear ranges of satraplatin in plasma or urine were 0.25mg·L^(-1)~10.0mg·L^(-1).The correlation coefficient r^(2) was 0.9952 and 0.9878,and the regression equation were A=(0.2118)C-0.0548 and A=0.1556C-0.0042 for plasma and urine,respectively.The average recoveries were 89%~112% in plasma and 82%~100% in urine,respectively.The RSD values of interday and intra-day assays were lower than 8.9% and 6.4% respectably.CONCLUSION This method is suitable for the preclinical pharmacokinetic studies of satraplatin in rats.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2006年第S2期731-733,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 赛特铂 大鼠 血浆 尿 原子吸收分光光度法 铂抗癌药 satraplatin rats plasma urine atomic absorption spectrometry oral platinum anticancer drug
  • 相关文献

参考文献8

  • 1李文钧,彭小英,马张英,郑永兴.口服抗肿瘤药赛特铂在大鼠的药动学[J].中国新药与临床杂志,2004,23(8):528-530. 被引量:1
  • 2马张英,李文钧,裘飞君,彭小英.高效液相色谱法测定卡铂粉针和水针剂的含量[J].中国医院药学杂志,2004,24(4):247-248. 被引量:8
  • 3李文钧,彭小英,马张英,郑永兴.赛特铂抗肿瘤作用的临床前观察[J].中国新药杂志,2003,12(8):643-645. 被引量:3
  • 4Hanada K,Nagai N,Ogata H.Quantitative determ ination of un-changed cisplatin in rat k idney and liver by h igh-performance liq-u id chromatography. J Chromatogr B B iom ed Appl . 1995
  • 5Kelland LR.An update on satraplatin:the first orally availab leplatinum anticancer drug. Expert Opinion on Investigational Drugs . 2000
  • 6M cKEAGE M J,KELLAND LR,BOXALL FE,et al.Schedu ledependency of orally adm in istered b is-acetato-amm ine-d ichloro-cyclohexylam ine-platinum(IV)(JM216)in vivo. Cancer Research . 1994
  • 7M cGahan MC,and Tyczkowska K.The determ ination of platinumin b iologicalmaterials by electrochem ical atom ic absorption spec-troscopy. Spectroch im ica Acta . 1987
  • 8Townsend DM,Marto JA,D eng M,et al.H igh pressure liqu idchromatography and mass spectrom etry characterization of thenephrotoxic b iotransformation products of C isplatin. D rugM etab D ispos . 2003

二级参考文献7

  • 1刘伟平,阙振寰,杨一昆,熊惠周.卡铂水溶液的光分解产物[J].药学学报,1996,31(1):72-74. 被引量:11
  • 2[1]Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug[J]. Expert Opin Investig Drugs, 2000, 9(6):1373-1382.
  • 3[2]See above
  • 4Kelland LR.An update on satraplatin: the first orally available platinum antieancer drug [J]. Expert Opin Investig Drugs,2000,9(6):1373-1382.
  • 5Screnci D, McKeage MJ, Galettis P, et al. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs[J]. Br J Cancer, 2000,82 (4) :966-972.
  • 6Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-platinure (IV) :an orally active platinum drug[J]. Cancer Res, 199353(11) :2581-2586.
  • 7陈启蒙.抗癌药卡铂的临床应用进展[J].中国医师杂志,2000,2(9):540-541. 被引量:16

共引文献9

同被引文献653

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部